295 related articles for article (PubMed ID: 36588164)
1. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
[TBL] [Abstract][Full Text] [Related]
2. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.
Herbert B; Patel D; Waddington SN; Eden ER; McAleenan A; Sun XM; Soutar AK
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1333-9. PubMed ID: 20448210
[TBL] [Abstract][Full Text] [Related]
3. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
Valenti V; Noto D; Giammanco A; Fayer F; Spina R; Altieri GI; Ingrassia V; Scrimali C; Barbagallo CM; Brucato F; Misiano G; Cefalù AB; Averna MR
Atherosclerosis; 2020 Jan; 292():209-214. PubMed ID: 31564372
[TBL] [Abstract][Full Text] [Related]
4. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9
Lammi C; Bollati C; Lecca D; Abbracchio MP; Arnoldi A
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31330826
[TBL] [Abstract][Full Text] [Related]
5. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Liu X; Bao X; Hu M; Chang H; Jiao M; Cheng J; Xie L; Huang Q; Li F; Li CY
Nature; 2020 Dec; 588(7839):693-698. PubMed ID: 33177715
[TBL] [Abstract][Full Text] [Related]
8. A novel angiogenic effect of PCSK9- regulated genes.
Zhan X; Jiang L; Wang L; Liu J; Kang S; Liu H; Lin L
Gene; 2023 Feb; 852():147051. PubMed ID: 36427678
[TBL] [Abstract][Full Text] [Related]
9. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
[TBL] [Abstract][Full Text] [Related]
11. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
12. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.
Shields BD; Koss B; Taylor EM; Storey AJ; West KL; Byrum SD; Mackintosh SG; Edmondson R; Mahmoud F; Shalin SC; Tackett AJ
Cancer Res; 2019 Mar; 79(6):1113-1123. PubMed ID: 30674537
[TBL] [Abstract][Full Text] [Related]
13. Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Grefhorst A; McNutt MC; Lagace TA; Horton JD
J Lipid Res; 2008 Jun; 49(6):1303-11. PubMed ID: 18354138
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.
Ranheim T; Mattingsdal M; Lindvall JM; Holla OL; Berge KE; Kulseth MA; Leren TP
J Cell Physiol; 2008 Nov; 217(2):459-67. PubMed ID: 18570182
[TBL] [Abstract][Full Text] [Related]
15. Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.
Yang QC; Wang S; Liu YT; Song A; Wu ZZ; Wan SC; Li HM; Sun ZJ
iScience; 2023 Jun; 26(6):106916. PubMed ID: 37305703
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.
Pandit S; Wisniewski D; Santoro JC; Ha S; Ramakrishnan V; Cubbon RM; Cummings RT; Wright SD; Sparrow CP; Sitlani A; Fisher TS
J Lipid Res; 2008 Jun; 49(6):1333-43. PubMed ID: 18354137
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells.
Suh JM; Son Y; Yoo JY; Goh Y; Seidah NG; Lee S; Bae YS
Neoplasia; 2021 Sep; 23(9):993-1001. PubMed ID: 34352405
[TBL] [Abstract][Full Text] [Related]
19. Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.
Saida Y; Brender JR; Yamamoto K; Mitchell JB; Krishna MC; Kishimoto S
Cancer Res; 2021 Jul; 81(13):3693-3705. PubMed ID: 33837042
[TBL] [Abstract][Full Text] [Related]
20. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
